Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 1/20 | 0.57 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.44 |
| ▸ | TUBB | P07437 | 3/20 | 0.44 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.44 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.44 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.44 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.44 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.44 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.44 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.44 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.44 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.44 |
| ▸ | TUBA1C | Q9BQE3 | 3/20 | 0.44 |
| ▸ | TUBB6 | Q9BUF5 | 3/20 | 0.44 |
| ▸ | TUBB2B | Q9BVA1 | 3/20 | 0.44 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4708595 | 0.90 | PDE2A (0.55) | PDE2ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5034754 | 0.90 | PDE2A (0.60) | PDE2ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5037345 | 0.82 | TUBB4A (0.45) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL6028217 | 0.82 | PDE2A (0.49) | PDE2ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6028000 | 0.81 | PDE2A (0.46) | PDE2ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6031160 | 0.81 | PDE2A (0.51) | PDE2ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL5034662 | 0.80 | PDE2A (0.86) | PDE2AGABRA1GABRG2GABRB3GABRA5 | |
| SCHEMBL6028359 | 0.80 | PDE2A (0.51) | PDE2ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL6028943 | 0.79 | PDE2A (0.44) | PDE2ATUBB4ATUBBTUBA3CTUBA1B | |
| SCHEMBL4707743 | 0.78 | PDE2A (0.48) | PDE2ATUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7410963-B2 | To treat diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate and abnormal regulation of neurotransmitter effect, with no perturbating effect on memory; autoinflammatory disorders; 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile | VIA PHARMACEUTICALS, INC. (US) | 2008-08-12 | — | — | US | claimed |
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2007-05-31 | — | — | US | claimed |
| EP-1548011-A1 | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof | NEURO3D (FR) | 2005-06-29 | — | — | EP | claimed |
| US-7410963-B2 | To treat diseases associated with abnormal regulation of intracellular cAMP and/or cGMP rate and abnormal regulation of neurotransmitter effect, with no perturbating effect on memory; autoinflammatory disorders; 3-(8-Methoxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-5-yl)-benzonitrile | VIA PHARMACEUTICALS, INC. (US) | 2008-08-12 | — | — | US | disclosed |
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | BAY CITY CAPITAL LLC | 2007-05-31 | — | — | US | disclosed |
| EP-1548011-A1 | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof | NEURO3D (FR) | 2005-06-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070123519-A1 | Benzo-1,4-diazepin-2-one derivatives as phosphodiesterase pde2 inhibitors, preparation and therapeutic use thereof | PDE12, PDE2A, PDE3A | PDE2A 2/4885TUBB4A 2980/4885TUBB 2223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.